Oric Pharmaceuticals Inc
NASDAQ:ORIC
Intrinsic Value
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ORIC.
Oric Pharmaceuticals Inc's market capitalization is 516.8m USD.
ORIC stock price is 7.67 USD.
ORIC.
ORIC. Open DCF Valuation
ORIC. Open Relative Valuation
ORIC has upside potential of 155% compared to the average analyst price target.
Open Wall St Estimates
ORIC has negative Free Cash Flow for the last twelve months.
ORIC's ROE (Return on Equity) has increased in the last 3 years from -46% to -45%, and is approaching profitability.
ORIC has negative Operating Income for the last twelve months.
ORIC has negative Net Income for the last twelve months.
ORIC's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 599% to -268%, and is approaching profitability.
ORIC's ROE (Return on Equity) for the past 12 months is negative and is equal to -45%.
ORIC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -268%.
ORIC has negative three-year average ROE (Return on Equity): -37%. The company is not efficient at transforming stockholders' equity into net income.
ORIC has negative three-year average ROIC (Return on Invested Capital): -594%. The company is not efficient at using invested capital to generate operating income.
ORIC's short-term assets (213m USD) exceed its short-term liabilties (20m USD).
ORIC's long-term assets (252m USD) exceed its long-term liabilties (28m USD).
ORIC's D/E (Debt to Equity) is very low and is equal to 0.
ORIC's Altman Z-Score is very high and is equal to 9.38.
Fundamental Analysis
Oric Pharmaceuticals Inc
Balance Sheet Decomposition
Oric Pharmaceuticals Inc
| Current Assets | 212.6m |
| Cash & Short-Term Investments | 208.2m |
| Other Current Assets | 4.4m |
| Non-Current Assets | 39.4m |
| Long-Term Investments | 26.9m |
| PP&E | 2.9m |
| Other Non-Current Assets | 9.7m |
| Current Liabilities | 20.5m |
| Accounts Payable | 944k |
| Accrued Liabilities | 19.5m |
| Non-Current Liabilities | 7.5m |
| Other Non-Current Liabilities | 7.5m |
Earnings Waterfall
Oric Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-110.8m
USD
|
|
Operating Income
|
-110.8m
USD
|
|
Other Expenses
|
10.1m
USD
|
|
Net Income
|
-100.7m
USD
|
Free Cash Flow Analysis
Oric Pharmaceuticals Inc
ORIC Profitability Score
Profitability Due Diligence
Oric Pharmaceuticals Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Oric Pharmaceuticals Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
ORIC Solvency Score
Solvency Due Diligence
Oric Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Oric Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ORIC Price Targets Summary
Oric Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ORIC
is 19.53 USD
with a low forecast of 15.15 USD and a high forecast of 26.25 USD.
Ownership
ORIC Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ORIC Price
Oric Pharmaceuticals Inc
| Average Annual Return | -28.39% |
| Standard Deviation of Annual Returns | 50.3% |
| Max Drawdown | -94% |
| Market Capitalization | 516.8m USD |
| Shares Outstanding | 67 380 000 |
| Percentage of Shares Shorted | 13.13% |
ORIC News
Last Important Events
Oric Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Oric Pharmaceuticals Inc
Company Profile
Oric Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 78 full-time employees. The company went IPO on 2020-04-24. The firm is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its product candidates include ORIC-101, ORIC-533, ORIC-944 and ORIC-114. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its ORIC-944, is being developed for prostate cancer and breast cancer.
You don't have any saved screeners yet
